Research

Three questions, starting with what I am working on now.

1 · Therapy · 2020 – present

Stopping metastasis

Targeting the HIF-1α-high, metastasis-driving subpopulation is more effective than targeting all cancer cells. A high-throughput screen of more than 12,000 compounds surfaced older statins as potent inhibitors of metastasis that act through a non-cholesterol, hypoxia-pathway mechanism; these are being developed as selective inhibitors of metastasis (SIM). With immunology collaborators, CD70-directed allogeneic CAR-NKT cells were built to target tumor, microenvironment, and alloreactive T cells together, as an off-the-shelf cell therapy for metastatic ccRCC.

Cell Rep Med 2025 · AACR abstracts 2023 – 2026 · patent applications
2 · Metastasis · 2015 – 2023

Tumor heterogeneity drives metastasis

Labelled VHL-null and VHL-restored ccRCC cells and followed them in immunocompetent mice and on the chick chorioallantoic membrane (CAM). The populations cooperate to form lung metastases, overturning the idea that motile cells seed metastasis on their own; HIF-1α in proliferative cells is the driver, with periostin and VHL-null exosomes carrying the cross-talk. Built the CRISPR VHL-knockout lines, the non-integrating lentiviral strategy that avoids Cas9 immune rejection, and the CAM xenograft protocols the lab now uses.

Signal Transduct Target Ther 2023 · Int J Mol Sci 2023 ×2 · Mol Ther Methods Clin Dev 2018 · JoVE 2020 ×2
3 · Origins · 2011 – 2019

Cancer stem cells and noncoding RNAs

Isolated CD105+ renal cancer stem cells and showed that endoglin maintains their self-renewal and chemoresistance; it induces EMT but is not sufficient for metastasis. Mapped microRNA and lncRNA circuits that regulate stemness and progression in kidney and bladder cancer, including miR-34a/CD44, MALAT1 and PVT1 as competing endogenous RNAs, and a SETD2/miR-335/Oct-4 axis.

Stem Cell Reports 2017 · Stem Cells Int 2019 · Oncotarget 2015, 2017 · J Urol 2014

Looking ahead

  • Define the non-cholesterol target of statins and advance SIM compounds to prevent ccRCC metastasis.
  • Bring off-the-shelf CD70 CAR-NKT therapy toward patients with metastatic ccRCC.
  • Explain why HIF-1α and HIF-2α drive mutually exclusive cell fates in ccRCC.